VIT Stock Overview
Engages in the sale and distribution of medicinal cannabis products in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vitura Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.086 |
| 52 Week High | AU$0.40 |
| 52 Week Low | AU$0.068 |
| Beta | 0.16 |
| 11 Month Change | 3.61% |
| 3 Month Change | -8.51% |
| 1 Year Change | -74.33% |
| 33 Year Change | -18.10% |
| 5 Year Change | n/a |
| Change since IPO | -74.71% |
Recent News & Updates
Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture
Sep 07
Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings
Aug 12Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Aug 12Recent updates
Vitura Health's (ASX:VIT) Soft Earnings Don't Show The Whole Picture
Sep 07Vitura Health Limited's (ASX:VIT) 26% Dip In Price Shows Sentiment Is Matching Earnings
Aug 12Vitura Health Limited (ASX:VIT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Aug 12The Market Doesn't Like What It Sees From Vitura Health Limited's (ASX:VIT) Earnings Yet As Shares Tumble 43%
Apr 25Does Vitura Health (ASX:VIT) Have A Healthy Balance Sheet?
Apr 11Investors Don't See Light At End Of Vitura Health Limited's (ASX:VIT) Tunnel And Push Stock Down 37%
Feb 27Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Feb 25Calculating The Fair Value Of Vitura Health Limited (ASX:VIT)
Dec 13Here's Why Shareholders Will Not Be Complaining About Vitura Health Limited's (ASX:VIT) CEO Pay Packet
Nov 21Is Now The Time To Put Vitura Health (ASX:VIT) On Your Watchlist?
Nov 01Here's Why We Think Vitura Health (ASX:VIT) Is Well Worth Watching
Jul 18Earnings Not Telling The Story For Cronos Australia Limited (ASX:CAU) After Shares Rise 111%
Sep 12If EPS Growth Is Important To You, Cronos Australia (ASX:CAU) Presents An Opportunity
Sep 05Shareholder Returns
| VIT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 3.6% | -4.8% | -1.3% |
| 1Y | -74.3% | 68.0% | 11.0% |
Return vs Industry: VIT underperformed the Australian Pharmaceuticals industry which returned 68% over the past year.
Return vs Market: VIT underperformed the Australian Market which returned 11% over the past year.
Price Volatility
| VIT volatility | |
|---|---|
| VIT Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: VIT has not had significant price volatility in the past 3 months.
Volatility Over Time: VIT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Tom Howitt | vitura.com.au |
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a medicinal cannabis clinic that offers telehealth consultations.
Vitura Health Limited Fundamentals Summary
| VIT fundamental statistics | |
|---|---|
| Market cap | AU$49.53m |
| Earnings (TTM) | AU$3.51m |
| Revenue (TTM) | AU$123.87m |
14.1x
P/E Ratio0.4x
P/S RatioIs VIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIT income statement (TTM) | |
|---|---|
| Revenue | AU$123.87m |
| Cost of Revenue | AU$89.65m |
| Gross Profit | AU$34.22m |
| Other Expenses | AU$30.71m |
| Earnings | AU$3.51m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0061 |
| Gross Margin | 27.63% |
| Net Profit Margin | 2.84% |
| Debt/Equity Ratio | 13.8% |
How did VIT perform over the long term?
See historical performance and comparison